UNSPSC 51386403: Balsalazide disodium

This classification denotes an anti-infective agent with the molecular formula C17H13N3O6.2NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XL6BJI034. European Medicines Agency schedules balsalazide disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35314. The term balsalazide disodium is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule balsalazide disodium under HS 29270000.

As of Q4 2014, BALSALAZIDE DISODIUM remains US FDA's Preferred Term for this commodity. Balsalazide disodium bears US NLM identifiers UMLS ID C0595398 and NCI Concept Code C47409. SMILES: C1CC(CCC1C(=O)NCCC(=O)[O-])/N=N/C2CCC(C(C2)C(=O)[O-])O.O.O.[NA+].[NA+].

UNSPSC 51386403 Balsalazide disodium is a Commodity code nominally identifying a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under it diverge significantly from that scope. The three most recent solicitations involve naloxone distribution systems, direct-to-manufacturer prescription program implementation, and generic multi-source pharmaceutical supply agreements—none of which center on balsalazide. The mismatch suggests either coding inconsistency in the sourcing jurisdictions or that this code functions as a broader pharmaceutical procurement category in practice. The issuing bodies include Seminole County, Florida (a county government health department); the Texas Health and Human Services Commission (a state agency); and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP, a cooperative vehicle administered by the Minnesota Department of Administration). This mix indicates both direct-buy and cooperative-purchasing activity at state and county levels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued an IFB on June 30, 2026 (due July 26, 2023—note the date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; vendors must provide unit costs, maintain insurance coverage including $5 million commercial general liability, and comply with E-Verify requirements. The Texas HHS Commission posted an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program with no formal evaluation criteria or budget disclosed. MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, requiring vendors to maintain two-of-three relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson, comply with cGMP and DSCSA certification, carry $2 million network security and professional liability coverage, and accept a 3 percent administrative fee with performance penalties ranging from $200 to $1,500 per violation; the contract term is two years with optional extensions.